步科股份(688160.SH):會以無框力矩電機作為主要產品去進行下游的佈局
格隆匯9月5日丨步科股份(688160.SH)近期在接待機構投資者調研時表示,公司上半年對戰略進行了梳理和升級,提出進一步鞏固並圍繞公司在機器人領域的核心優勢,洞察並深入相關其它行業 N,構建步科 1+N 的戰略版圖。公司將持續加大機器人核心部件的相關研究,持續為機器人客户提供創新的解決方案,公司會以無框力矩電機作為主要產品去進行下游的佈局,同時也不僅限於提供動力方向上的這一個產品,還會結合公司在電磁設計、編碼器、減速機和顯示交互等方面的技術能力,為機器人客户提供更多延展性的整體產品解決方案。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.